NCT00722800View on ClinicalTrials.gov

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

drospirenone and ethinyl estradiol (YAZ)

1 tablet daily for 24 weeks

DRUG

Placebo

1 tablet daily for 24 weeks

Trial Locations (1)

02114

Clinical Unit for Research Trials in Skin, Boston

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Massachusetts General Hospital

OTHER